Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
Background Despite recent advances in the treatment of advanced non-small-cell lung
cancer, there remains a need for effective treatments for progressive disease. We assessed …
cancer, there remains a need for effective treatments for progressive disease. We assessed …
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
RS Herbst, P Baas, DW Kim, E Felip, JL Pérez-Gracia… - The Lancet, 2016 - Elsevier
Background Despite recent advances in the treatment of advanced non-small-cell lung
cancer, there remains a need for effective treatments for progressive disease. We assessed …
cancer, there remains a need for effective treatments for progressive disease. We assessed …
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
RS Herbst, P Baas, DW Kim, E Felip… - The …, 2016 - s-space.snu.ac.kr
Background Despite recent advances in the treatment of advanced non-small-cell lung
cancer, there remains a need for effective treatments for progressive disease. We assessed …
cancer, there remains a need for effective treatments for progressive disease. We assessed …
[PDF][PDF] Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
RS Herbst, P Baas, DW Kim, E Felip, JL Pérez-Gracia… - Lancet, 2016 - ctg.queensu.ca
Background Despite recent advances in the treatment of advanced non-small-cell lung
cancer, there remains a need for effective treatments for progressive disease. We assessed …
cancer, there remains a need for effective treatments for progressive disease. We assessed …
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.
RS Herbst, P Baas, DW Kim, E Felip… - Lancet (London …, 2015 - europepmc.org
Background Despite recent advances in the treatment of advanced non-small-cell lung
cancer, there remains a need for effective treatments for progressive disease. We assessed …
cancer, there remains a need for effective treatments for progressive disease. We assessed …
[引用][C] Pembrolizumab versus docetaxel for previously treated, PD‐L1‐positive, advanced non‐small‐cell lung cancer (KEYNOTE‐010): a randomised controlled trial
R Herbst - N Engl J Med, 2016 - cir.nii.ac.jp
Pembrolizumab versus docetaxel for previously treated, PD‐L1‐positive, advanced non‐small‐cell
lung cancer (KEYNOTE‐010): a randomised controlled trial | CiNii Research CiNii 国立情報学 …
lung cancer (KEYNOTE‐010): a randomised controlled trial | CiNii Research CiNii 国立情報学 …
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): A randomised controlled trial
RS Herbst, P Baas, DW Kim, E Felip… - The …, 2016 - snucm.elsevierpure.com
Background Despite recent advances in the treatment of advanced non-small-cell lung
cancer, there remains a need for effective treatments for progressive disease. We assessed …
cancer, there remains a need for effective treatments for progressive disease. We assessed …
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
RS Herbst, P Baas, DW Kim, E Felip, JL Pérez-Gracia… - 2016 - pubmed.ncbi.nlm.nih.gov
Background Despite recent advances in the treatment of advanced non-small-cell lung
cancer, there remains a need for effective treatments for progressive disease. We assessed …
cancer, there remains a need for effective treatments for progressive disease. We assessed …
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
RS Herbst, P Baas, DW Kim, E Felip… - …, 2016 - scholarworks.bwise.kr
Background Despite recent advances in the treatment of advanced non-small-cell lung
cancer, there remains a need for effective treatments for progressive disease. We assessed …
cancer, there remains a need for effective treatments for progressive disease. We assessed …
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
RS Herbst, P Baas, DW Kim, E Felip, JL Pérez-Gracia… - The Lancet, 2016 - infona.pl
Despite recent advances in the treatment of advanced non-small-cell lung cancer, there
remains a need for effective treatments for progressive disease. We assessed the efficacy of …
remains a need for effective treatments for progressive disease. We assessed the efficacy of …